Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

An experimental treatment showed promising early results for reducing the risk of dementia related to Alzheimer’s for ...

The results boost hopes similar treatments being developed to target more common forms of Alzheimer's - that appear when ...

This appeal is filed by the Assessee as against the Revision order dated 22.02.2024 passed by the Principal Commissioner of Income Tax, Vadodara-1 arising out of the assessment order passed under ...

House Bill 495 and Senate Bill 2 brought debate and emotion to the House floor as both measures directly affect the LGBTQ+ ...

Authors Key Points Media Contact For general and media inquiries and to book our experts, please contact: [email protected] Background About 40.3 million Americans have a substance use disorder (SUD).

Ashleigh Ellerton, 29, was told she was 'too young' to get the disease. The doctor said that, given she didn't have a family history of the illness, it was unlikely to be anything serious.

The Department of Veterans Affairs, which has a huge presence in the CSRA, announced Monday it will phase out medical treatments for gender dysphoria.

The new tablet, known as Ryeqo or relugolix-estradiol-norethisterone, has been approved to treat women of reproductive age ...

Genetic changes alone don’t fully explain tumor growth in NF-1, pointing to other contributing factors. This insight may ...